探索精神分裂症阳性与阴性症状量表五因素模型的共识。
Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia.
机构信息
Clinical Brain Disorders Branch, National Institute of Mental Health, NIH, Bethesda, MD 20892-1377, USA.
出版信息
Schizophr Res. 2012 May;137(1-3):246-50. doi: 10.1016/j.schres.2012.01.031. Epub 2012 Feb 21.
Abstract
Although the developers of the Positive and Negative Syndrome Scale (PANSS) grouped items into three subscales, factor analyses indicate that a five-factor model better characterizes PANSS data. However, lack of consensus on which model to use limits the comparability of PANSS variables across studies. We counted "votes" from published factor analyses to derive consensus models. One of these combined superior fit in our Caucasian sample (n=458, CFI=.970), and in distinct Japanese sample (n=164, CFI=.964), relative to the original three-subscale model, with a sorting of items into factors that was highly consistent across the studies reviewed.
摘要
虽然阳性和阴性症状量表（PANSS）的开发者将项目分为三个分量表，但因素分析表明，五因素模型能更好地描述 PANSS 数据。然而，对于使用哪种模型缺乏共识，限制了 PANSS 变量在研究之间的可比性。我们对已发表的因素分析进行了“计数”，以得出共识模型。其中一个模型在我们的白种人样本（n=458，CFI=.970）和独特的日本样本（n=164，CFI=.964）中表现出更好的拟合，与原始的三分量表模型相比，与综述研究中高度一致的项目分类因素相比。
相似文献
1
Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia.
Schizophr Res. 2012 May;137(1-3):246-50. doi: 10.1016/j.schres.2012.01.031. Epub 2012 Feb 21.
2
Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia.
Schizophr Res. 2013 Jan;143(1):77-83. doi: 10.1016/j.schres.2012.10.020. Epub 2012 Nov 30.
3
How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS.
Cogn Neuropsychiatry. 2013 May;18(3):243-51. doi: 10.1080/13546805.2012.730995. Epub 2012 Nov 12.
4
Validation of a five-factor model of a Chinese Mandarin version of the Positive and Negative Syndrome Scale (CMV-PANSS) in a sample of 813 schizophrenia patients.
Schizophr Res. 2015 Dec;169(1-3):489-490. doi: 10.1016/j.schres.2015.09.011. Epub 2015 Oct 9.
5
The Brazilian standardization of the MATRICS consensus cognitive battery (MCCB): Psychometric study.
Schizophr Res. 2017 Jul;185:148-153. doi: 10.1016/j.schres.2017.01.006. Epub 2017 Jan 17.
6
Scales for assessment of depression in schizophrenia: Factor analysis of calgary depression rating scale and hamilton depression rating scale.
Psychiatry Res. 2017 Jun;252:333-339. doi: 10.1016/j.psychres.2017.03.018. Epub 2017 Mar 9.
7
Internal consistency, temporal stability and neuropsychological correlates of three cognitive components of the Positive and Negative Syndrome Scale (PANSS).
Schizophr Res. 1999 Jul 27;38(1):27-35. doi: 10.1016/s0920-9964(99)00004-3.
8
Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the positive and negative syndrome scale.
Schizophr Bull. 2000;26(1):167-77. doi: 10.1093/oxfordjournals.schbul.a033437.
9
Psychometric validation of the consensus five-factor model of the Positive and Negative Syndrome Scale.
Compr Psychiatry. 2015 Oct;62:204-8. doi: 10.1016/j.comppsych.2015.07.015. Epub 2015 Jul 29.
10
Subscale structure for the Positive and Negative Syndrome Scale (PANSS): a proposed solution focused on clinical validity.
Psychiatry Res. 2013 Jan 30;205(1-2):137-42. doi: 10.1016/j.psychres.2012.08.019. Epub 2012 Sep 10.
引用本文的文献
1
The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trial.
Psychopharmacology (Berl). 2025 Aug 16. doi: 10.1007/s00213-025-06884-x.
2
Recent cannabis use affects the association between baseline immune markers and long-term outcomes in psychosis.
Transl Psychiatry. 2025 Aug 14;15(1):282. doi: 10.1038/s41398-025-03498-x.
3
Binomial order is a speech marker of psychosis and thought disorder.
Sci Rep. 2025 Aug 6;15(1):28819. doi: 10.1038/s41598-025-14681-x.
4
Theory-of-mind improvement in schizophrenia after integrative cognitive remediation: which patients benefit more?
Schizophr Res Cogn. 2025 Jul 22;42:100380. doi: 10.1016/j.scog.2025.100380. eCollection 2025 Dec.
5
A dimensional approach to psychosis: identifying cognition, depression, and thought disorder factors in a clinical sample.
Schizophrenia (Heidelb). 2025 Jul 14;11(1):97. doi: 10.1038/s41537-025-00641-x.
6
Altered cortical thickness associated with psychotic symptoms and cognitive profiles in involuntarily hospitalized, first-episode, drug-naive patients with schizophrenia.
Front Psychiatry. 2025 Jun 24;16:1596991. doi: 10.3389/fpsyt.2025.1596991. eCollection 2025.
7
White matter microstructure alterations in early psychosis and schizophrenia.
Transl Psychiatry. 2025 May 23;15(1):179. doi: 10.1038/s41398-025-03397-1.
8
Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial.
Neuropsychiatr Dis Treat. 2025 May 14;21:1047-1055. doi: 10.2147/NDT.S510471. eCollection 2025.
9
Role of peripheral cytokines and orbitofrontal cortex subregion structure in schizophrenia agitation.
Sci Rep. 2025 Apr 23;15(1):14125. doi: 10.1038/s41598-025-99033-5.
10
COSMIN systematic review and meta-analysis of the measurement properties of the Positive and Negative Syndrome Scale (PANSS).
EClinicalMedicine. 2025 Apr 11;82:103155. doi: 10.1016/j.eclinm.2025.103155. eCollection 2025 Apr.
本文引用的文献
1
Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling.
Eur Psychiatry. 2012 Aug;27(6):396-400. doi: 10.1016/j.eurpsy.2011.01.010. Epub 2011 Jun 30.
2
Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
Schizophr Res. 2011 Sep;131(1-3):75-81. doi: 10.1016/j.schres.2011.05.018. Epub 2011 Jun 22.
3
The SIGMAR1 gene is associated with a risk of schizophrenia and activation of the prefrontal cortex.
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1309-15. doi: 10.1016/j.pnpbp.2011.04.008. Epub 2011 Apr 28.
4
Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia.
Schizophr Bull. 2011 Mar;37(2):291-9. doi: 10.1093/schbul/sbq104. Epub 2010 Sep 22.
5
Cognitive factor structure and invariance in people with schizophrenia, their unaffected siblings, and controls.
Schizophr Bull. 2011 Nov;37(6):1157-67. doi: 10.1093/schbul/sbq018. Epub 2010 Mar 29.
6
Principal-component analyses of PANSS and SANS-SAPS in schizophrenia: their stability in an acute phase.
Eur Psychiatry. 1995;10(2):97-106. doi: 10.1016/0924-9338(96)80320-8.
7
Theory of mind in schizophrenia: the role of clinical symptomatology and neurocognition in understanding other people's thoughts and intentions.
Psychiatry Res. 2009 Jan 30;165(1-2):19-26. doi: 10.1016/j.psychres.2007.10.021. Epub 2008 Dec 14.
8
Insight, cognitive dysfunction and symptomatology in schizophrenia.
Eur Arch Psychiatry Clin Neurosci. 2008 Oct;258(7):402-5. doi: 10.1007/s00406-008-0809-8. Epub 2008 Apr 24.
9
Computerized measurement of negative symptoms in schizophrenia.
J Psychiatr Res. 2008 Aug;42(10):827-36. doi: 10.1016/j.jpsychires.2007.08.008. Epub 2007 Oct 24.
10
Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.
J Clin Psychopharmacol. 2007 Oct;27(5):431-6. doi: 10.1097/jcp/.0b013e31814cfabd.
Zotero 插件